SlideShare a Scribd company logo
1 of 1
DS MC DS/AD OC AD
Groups
MicrohemorrhageCount
YC
Frontal Cortex Microhemorrhages: Comparison in Down Syndrome and Alzheimers Disease
James C. Fitch1, Paulina R. Davis1,2, Frederick A. Schmitt1,3, Elizabeth Head1,2
University of Kentucky, Sanders Brown Center on Aging1, Dept. of Pharmacology & Nutritional Sciences2,
Department of Neurology3, Lexington, KY, United States; 2 , Lexington, KY, United States;
Subjects: 46 samples individuals with DS, AD, DS with AD, along with their age matched
controls.
Brain Tissue Preparation:
• Frontal cortex brain tissue was used from each case.
• Tissue was sectioned 50 um thick using a vibratome.
Prussian Blue Staining and MH Quantification:
• A solution of potassium ferrocyanide in acidic solution was used to stain iron rich
hemoglobin blue in the frontal cortex tissue
• Only iron in the extracellular matrix is colorized (indicative of MH).
• Must be within 2 cell diameters of a blood vessel to be considered an MH.
Sample Analysis:
• 6 images were captured at 20X magnification (3 superficial layer and 3 of corresponding
deep layer) and MH counted for each tissue
• Data is represented as total MH count per case.
Alzheimer’s disease (AD) is the most common cause of dementia in the
elderly. The hallmark lesions of AD include neurofibrillary tangles (NFTs) and
plaques that are made up of the β-amyloid protein (Aβ), resulting from cleavage
of the amyloid precursor protein (APP). Individuals with Down Syndrome (DS) or
trisomy 21 have an over expression of APP as the gene for this protein is on
chromosome 21. Thus adults with DS develop AD pathology in a progressive age-
dependent manner. Therfore, DS individuals are at high risk for the development
of dementia. By 40 years of age, all individuals with DS have full blown
neuropathological changes, including senile plaques and neurofibrillary tangles,
consistent with AD. However, clinical signs of dementia are not seen in DS
individuals for another decade, over 50 years of age. Cerebrovascular
dysfunction may be an important contributor to brain aging in people with DS.
Increased cerebral amyloid angiopathy (CAA) is seen in individuals with DS due
to the overexpression of APP. Thus, we hypothesized that there may be an age-
dependent increase in microhemorrhages (MH) in DS and due to AD.
Materials and Methods
• There was no age dependent increase in MH count in control cases ranging
2 to 88 years.
• Compared to their aged matched controls, both DS/AD and AD showed
noteworthy differences in MH count.
• When comparing DS/AD to AD there was also a important difference
between groups, showing that DS in conjunction with AD further increases
MH count more than AD.
• Clinical trials designed for DS with AD may target this pathology specifically,
or that adverse responses related to MH may need to be considered
Introduction Results
Conclusions
Acknowledgements
Funded by NIH/DHHS xxx/xxx
Results
Future Directions
• Future directions of this study will investigate the association between Aβ
accumulation in CAA to the frequency of MH.
• By looking for IgG in different brain tissue samples, the type and strength of the
immune response can be learned to gain a better understanding of the response to
diseases such as DS and AD.
2. Representation MH Count From Each Group
Table 1: Grouping used in study. Average ages, post mortem interval, and average bleed
count per frame. *() indicates standard deviation.
Group N Age* PMI* MH Count*
Young controls (YC) 6 17.5 (16.2) 14.0 (7.4) 0.3 (0.5)
Middle aged controls (MC) 9 50.3 (9.1) 15.5 (6.1) 2.9 (5.9)
Old controls (OC) 8 81.0 (4.7) 3.4 (3.5) 2.0 (2.3)
Young DS (DS) 7 16.9 (16.9) 20.8 (12.8) 0.7 (1.3)
DS with AD (DS/AD) 8 53.4 (7.7) 9.3 (7.6) 17.0 (11.0)
Sporadic AD (AD) 7 83.3 (5.5) 5.0 (2.4) 10.9 (9.3)
Figure 1: Prussian Blue stained tissue representing average MH counts for each study
group. YC)-Young Controls, MC)-Middle Aged Controls, OC)-Old Controls, DS)-Young Down
syndrome, DS/AD) Down syndrome with Alzheimer’s disease, AD)-Sporadic Alzheimer’s
disease. Arrows indicate MH , arrow head indicate the location of blood vessels.
Subject Groups and MH Counts
Figure 2: A significant difference in MH counts is seen when comparing, DS/AD
(p=<0.05), to all groups. Both DS/AD and AD showed a significant difference in MH count
from their aged matched controls (p=<0.001) and (p=<0.018) respectively. Most notably,
there was a significant difference between DS/AD and AD (p=<0.029).
Identifying Microhemorrhages
Figure 1: Illustration of MH labeled by Prussian Blue. It is within appropriate proximity of blood
vessels (two cell diameter) and is punctate in nature. Arrows indicate MH, Arrowheads indicate
blood vessels
DS/AD
YC
MC
OC
DS
AD
Tissue Sample and Preparation
DS/AD
4. Average Microhemorrhage Count

More Related Content

What's hot

Eli Silber - Stem cells
Eli Silber - Stem cellsEli Silber - Stem cells
Eli Silber - Stem cellsMS Trust
 
Langerhanse Cell Histiocytosis
Langerhanse Cell HistiocytosisLangerhanse Cell Histiocytosis
Langerhanse Cell Histiocytosisdrajayalwar
 
Homocysteine and Alzheimer's Disease
Homocysteine and Alzheimer's DiseaseHomocysteine and Alzheimer's Disease
Homocysteine and Alzheimer's DiseaseYifan (Ronnie) Li
 
Updates of mri criteria for diagnosis of ms
Updates of mri criteria for diagnosis of msUpdates of mri criteria for diagnosis of ms
Updates of mri criteria for diagnosis of msMohammad Aboulwafa
 
Management strategies in multiple sclerosis
Management strategies in multiple sclerosisManagement strategies in multiple sclerosis
Management strategies in multiple sclerosisAmr Hassan
 
Neuroblastoma research paper(2015)
Neuroblastoma research paper(2015)Neuroblastoma research paper(2015)
Neuroblastoma research paper(2015)Ruchi
 
Neuropathologic asses alzh dis
Neuropathologic asses alzh disNeuropathologic asses alzh dis
Neuropathologic asses alzh disayhan bölük
 
Lecturas recomendadas neuro oncología 2012
Lecturas recomendadas neuro oncología 2012Lecturas recomendadas neuro oncología 2012
Lecturas recomendadas neuro oncología 2012INUB
 
Dr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a RelapseDr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a RelapseMS Trust
 
Neurological Implications of von-Hippel Lindau disease
Neurological Implications of von-Hippel Lindau diseaseNeurological Implications of von-Hippel Lindau disease
Neurological Implications of von-Hippel Lindau diseaseAde Wijaya
 

What's hot (19)

Eli Silber - Stem cells
Eli Silber - Stem cellsEli Silber - Stem cells
Eli Silber - Stem cells
 
241 genetic influence on carotid atherosclerosis
241 genetic influence on carotid atherosclerosis241 genetic influence on carotid atherosclerosis
241 genetic influence on carotid atherosclerosis
 
Genetic influence ppt11
Genetic influence ppt11Genetic influence ppt11
Genetic influence ppt11
 
Can you inherit a carotid plaque
Can you inherit a carotid plaqueCan you inherit a carotid plaque
Can you inherit a carotid plaque
 
Esv3n1
Esv3n1Esv3n1
Esv3n1
 
Langerhanse Cell Histiocytosis
Langerhanse Cell HistiocytosisLangerhanse Cell Histiocytosis
Langerhanse Cell Histiocytosis
 
T2T_NEDA_KS_20180413
T2T_NEDA_KS_20180413T2T_NEDA_KS_20180413
T2T_NEDA_KS_20180413
 
Homocysteine and Alzheimer's Disease
Homocysteine and Alzheimer's DiseaseHomocysteine and Alzheimer's Disease
Homocysteine and Alzheimer's Disease
 
Updates of mri criteria for diagnosis of ms
Updates of mri criteria for diagnosis of msUpdates of mri criteria for diagnosis of ms
Updates of mri criteria for diagnosis of ms
 
Management strategies in multiple sclerosis
Management strategies in multiple sclerosisManagement strategies in multiple sclerosis
Management strategies in multiple sclerosis
 
Neuroblastoma research paper(2015)
Neuroblastoma research paper(2015)Neuroblastoma research paper(2015)
Neuroblastoma research paper(2015)
 
Neuropathologic asses alzh dis
Neuropathologic asses alzh disNeuropathologic asses alzh dis
Neuropathologic asses alzh dis
 
Lecturas recomendadas neuro oncología 2012
Lecturas recomendadas neuro oncología 2012Lecturas recomendadas neuro oncología 2012
Lecturas recomendadas neuro oncología 2012
 
Stroke 2008-delano-wood-794-9
Stroke 2008-delano-wood-794-9Stroke 2008-delano-wood-794-9
Stroke 2008-delano-wood-794-9
 
Hartings, Jed - Outcome
Hartings, Jed - OutcomeHartings, Jed - Outcome
Hartings, Jed - Outcome
 
Traffic related air pollution and cognitive function in a cohort of older men
Traffic related air pollution and cognitive function in a cohort of older menTraffic related air pollution and cognitive function in a cohort of older men
Traffic related air pollution and cognitive function in a cohort of older men
 
Genetics of Scleroderma: Towards Personalized Medicine in the Genomic Age
Genetics of Scleroderma: Towards Personalized Medicine in the Genomic AgeGenetics of Scleroderma: Towards Personalized Medicine in the Genomic Age
Genetics of Scleroderma: Towards Personalized Medicine in the Genomic Age
 
Dr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a RelapseDr Trevor Pickersgill - Diagnosing a Relapse
Dr Trevor Pickersgill - Diagnosing a Relapse
 
Neurological Implications of von-Hippel Lindau disease
Neurological Implications of von-Hippel Lindau diseaseNeurological Implications of von-Hippel Lindau disease
Neurological Implications of von-Hippel Lindau disease
 

Similar to James_Fitch_Poster Presentation

Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptxClinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptxPramod Krishnan
 
2007 CJD Presentation - Graham Steel
2007 CJD Presentation - Graham Steel2007 CJD Presentation - Graham Steel
2007 CJD Presentation - Graham SteelGraham Steel
 
The comprehensive guide to autism
The comprehensive guide to autismThe comprehensive guide to autism
The comprehensive guide to autismSpringer
 
Mini-mental state examination in patients with hepatic encephalopathy and liv...
Mini-mental state examination in patients with hepatic encephalopathy and liv...Mini-mental state examination in patients with hepatic encephalopathy and liv...
Mini-mental state examination in patients with hepatic encephalopathy and liv...Enrique Moreno Gonzalez
 
1 s2.0-s0887899413001999-main
1 s2.0-s0887899413001999-main1 s2.0-s0887899413001999-main
1 s2.0-s0887899413001999-mainllilia
 
Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...
Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...
Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...cililla
 
Neuroradiology in ms
Neuroradiology in msNeuroradiology in ms
Neuroradiology in msAmr Hassan
 
Neuroradiology in dementia
Neuroradiology in dementiaNeuroradiology in dementia
Neuroradiology in dementiaNeurologyKota
 
WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1
WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1
WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1Jerry Duncan
 
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...Champlain Regional Coordination Centre
 
Neuropathologic asses alzh dis
Neuropathologic asses alzh disNeuropathologic asses alzh dis
Neuropathologic asses alzh disayhan bölük
 
Different gray matter patterns in chronic schizophrenia and chronic bipolar d...
Different gray matter patterns in chronic schizophrenia and chronic bipolar d...Different gray matter patterns in chronic schizophrenia and chronic bipolar d...
Different gray matter patterns in chronic schizophrenia and chronic bipolar d...Benjamin Cortes
 
Nardilisina marcador de morbi mortalidad en infarto maligno
Nardilisina marcador de morbi mortalidad en infarto malignoNardilisina marcador de morbi mortalidad en infarto maligno
Nardilisina marcador de morbi mortalidad en infarto malignoHNERM
 
Is there a relation between sudden
Is there a relation between suddenIs there a relation between sudden
Is there a relation between suddendiegotorreblancavill
 
Volunteers, assessments, brains and research: the story of Brains for Dementi...
Volunteers, assessments, brains and research: the story of Brains for Dementi...Volunteers, assessments, brains and research: the story of Brains for Dementi...
Volunteers, assessments, brains and research: the story of Brains for Dementi...National Centre for Mental Health (NCMH)
 
Status ADRD Research 10-27-2020.pptx
Status ADRD Research 10-27-2020.pptxStatus ADRD Research 10-27-2020.pptx
Status ADRD Research 10-27-2020.pptxssuser65002f
 
Status of ADRD Research 10-27-2020.pptx
Status of ADRD Research 10-27-2020.pptxStatus of ADRD Research 10-27-2020.pptx
Status of ADRD Research 10-27-2020.pptxssuser65002f
 

Similar to James_Fitch_Poster Presentation (20)

Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptxClinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
 
Dementia nmt
Dementia nmtDementia nmt
Dementia nmt
 
Honors Thesis
Honors ThesisHonors Thesis
Honors Thesis
 
2007 CJD Presentation - Graham Steel
2007 CJD Presentation - Graham Steel2007 CJD Presentation - Graham Steel
2007 CJD Presentation - Graham Steel
 
The comprehensive guide to autism
The comprehensive guide to autismThe comprehensive guide to autism
The comprehensive guide to autism
 
Mini-mental state examination in patients with hepatic encephalopathy and liv...
Mini-mental state examination in patients with hepatic encephalopathy and liv...Mini-mental state examination in patients with hepatic encephalopathy and liv...
Mini-mental state examination in patients with hepatic encephalopathy and liv...
 
1 s2.0-s0887899413001999-main
1 s2.0-s0887899413001999-main1 s2.0-s0887899413001999-main
1 s2.0-s0887899413001999-main
 
Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...
Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...
Epidemiología del envejecimiento y trastornos cognitivos asociados prevalenci...
 
Never stop k_sv1.4
Never stop k_sv1.4Never stop k_sv1.4
Never stop k_sv1.4
 
Neuroradiology in ms
Neuroradiology in msNeuroradiology in ms
Neuroradiology in ms
 
Neuroradiology in dementia
Neuroradiology in dementiaNeuroradiology in dementia
Neuroradiology in dementia
 
WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1
WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1
WBRT vs GK Surgery_Cooper Univ_1507167_WhitePaper1
 
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
Type 2 Diabetes and Dementia: What's the link? A Review of the Metabolic and ...
 
Neuropathologic asses alzh dis
Neuropathologic asses alzh disNeuropathologic asses alzh dis
Neuropathologic asses alzh dis
 
Different gray matter patterns in chronic schizophrenia and chronic bipolar d...
Different gray matter patterns in chronic schizophrenia and chronic bipolar d...Different gray matter patterns in chronic schizophrenia and chronic bipolar d...
Different gray matter patterns in chronic schizophrenia and chronic bipolar d...
 
Nardilisina marcador de morbi mortalidad en infarto maligno
Nardilisina marcador de morbi mortalidad en infarto malignoNardilisina marcador de morbi mortalidad en infarto maligno
Nardilisina marcador de morbi mortalidad en infarto maligno
 
Is there a relation between sudden
Is there a relation between suddenIs there a relation between sudden
Is there a relation between sudden
 
Volunteers, assessments, brains and research: the story of Brains for Dementi...
Volunteers, assessments, brains and research: the story of Brains for Dementi...Volunteers, assessments, brains and research: the story of Brains for Dementi...
Volunteers, assessments, brains and research: the story of Brains for Dementi...
 
Status ADRD Research 10-27-2020.pptx
Status ADRD Research 10-27-2020.pptxStatus ADRD Research 10-27-2020.pptx
Status ADRD Research 10-27-2020.pptx
 
Status of ADRD Research 10-27-2020.pptx
Status of ADRD Research 10-27-2020.pptxStatus of ADRD Research 10-27-2020.pptx
Status of ADRD Research 10-27-2020.pptx
 

James_Fitch_Poster Presentation

  • 1. DS MC DS/AD OC AD Groups MicrohemorrhageCount YC Frontal Cortex Microhemorrhages: Comparison in Down Syndrome and Alzheimers Disease James C. Fitch1, Paulina R. Davis1,2, Frederick A. Schmitt1,3, Elizabeth Head1,2 University of Kentucky, Sanders Brown Center on Aging1, Dept. of Pharmacology & Nutritional Sciences2, Department of Neurology3, Lexington, KY, United States; 2 , Lexington, KY, United States; Subjects: 46 samples individuals with DS, AD, DS with AD, along with their age matched controls. Brain Tissue Preparation: • Frontal cortex brain tissue was used from each case. • Tissue was sectioned 50 um thick using a vibratome. Prussian Blue Staining and MH Quantification: • A solution of potassium ferrocyanide in acidic solution was used to stain iron rich hemoglobin blue in the frontal cortex tissue • Only iron in the extracellular matrix is colorized (indicative of MH). • Must be within 2 cell diameters of a blood vessel to be considered an MH. Sample Analysis: • 6 images were captured at 20X magnification (3 superficial layer and 3 of corresponding deep layer) and MH counted for each tissue • Data is represented as total MH count per case. Alzheimer’s disease (AD) is the most common cause of dementia in the elderly. The hallmark lesions of AD include neurofibrillary tangles (NFTs) and plaques that are made up of the β-amyloid protein (Aβ), resulting from cleavage of the amyloid precursor protein (APP). Individuals with Down Syndrome (DS) or trisomy 21 have an over expression of APP as the gene for this protein is on chromosome 21. Thus adults with DS develop AD pathology in a progressive age- dependent manner. Therfore, DS individuals are at high risk for the development of dementia. By 40 years of age, all individuals with DS have full blown neuropathological changes, including senile plaques and neurofibrillary tangles, consistent with AD. However, clinical signs of dementia are not seen in DS individuals for another decade, over 50 years of age. Cerebrovascular dysfunction may be an important contributor to brain aging in people with DS. Increased cerebral amyloid angiopathy (CAA) is seen in individuals with DS due to the overexpression of APP. Thus, we hypothesized that there may be an age- dependent increase in microhemorrhages (MH) in DS and due to AD. Materials and Methods • There was no age dependent increase in MH count in control cases ranging 2 to 88 years. • Compared to their aged matched controls, both DS/AD and AD showed noteworthy differences in MH count. • When comparing DS/AD to AD there was also a important difference between groups, showing that DS in conjunction with AD further increases MH count more than AD. • Clinical trials designed for DS with AD may target this pathology specifically, or that adverse responses related to MH may need to be considered Introduction Results Conclusions Acknowledgements Funded by NIH/DHHS xxx/xxx Results Future Directions • Future directions of this study will investigate the association between Aβ accumulation in CAA to the frequency of MH. • By looking for IgG in different brain tissue samples, the type and strength of the immune response can be learned to gain a better understanding of the response to diseases such as DS and AD. 2. Representation MH Count From Each Group Table 1: Grouping used in study. Average ages, post mortem interval, and average bleed count per frame. *() indicates standard deviation. Group N Age* PMI* MH Count* Young controls (YC) 6 17.5 (16.2) 14.0 (7.4) 0.3 (0.5) Middle aged controls (MC) 9 50.3 (9.1) 15.5 (6.1) 2.9 (5.9) Old controls (OC) 8 81.0 (4.7) 3.4 (3.5) 2.0 (2.3) Young DS (DS) 7 16.9 (16.9) 20.8 (12.8) 0.7 (1.3) DS with AD (DS/AD) 8 53.4 (7.7) 9.3 (7.6) 17.0 (11.0) Sporadic AD (AD) 7 83.3 (5.5) 5.0 (2.4) 10.9 (9.3) Figure 1: Prussian Blue stained tissue representing average MH counts for each study group. YC)-Young Controls, MC)-Middle Aged Controls, OC)-Old Controls, DS)-Young Down syndrome, DS/AD) Down syndrome with Alzheimer’s disease, AD)-Sporadic Alzheimer’s disease. Arrows indicate MH , arrow head indicate the location of blood vessels. Subject Groups and MH Counts Figure 2: A significant difference in MH counts is seen when comparing, DS/AD (p=<0.05), to all groups. Both DS/AD and AD showed a significant difference in MH count from their aged matched controls (p=<0.001) and (p=<0.018) respectively. Most notably, there was a significant difference between DS/AD and AD (p=<0.029). Identifying Microhemorrhages Figure 1: Illustration of MH labeled by Prussian Blue. It is within appropriate proximity of blood vessels (two cell diameter) and is punctate in nature. Arrows indicate MH, Arrowheads indicate blood vessels DS/AD YC MC OC DS AD Tissue Sample and Preparation DS/AD 4. Average Microhemorrhage Count